ImmunityBio (IBRX) Receivables - Other (2015 - 2026)

ImmunityBio (IBRX) has 12 years of Receivables - Other data on file, last reported at $3000.0 in Q1 2026.

• On a quarterly basis, Receivables - Other fell 95.45% year-over-year to $3000.0 in Q1 2026; TTM through Mar 2026 was $3000.0, a 95.45% decrease from a year earlier, with the FY2025 full-year figure at $46000.0, down 77.0% from the prior year.
• Receivables - Other for Q1 2026 stood at $3000.0, down from $46000.0 in the prior quarter.
• Over the last five years, Receivables - Other for IBRX reached as high as $5.0 million in Q2 2022 and fell as low as $3000.0 in Q1 2026.
• Historically, Receivables - Other has averaged $1.7 million across 5 years, with a median of $1.7 million in 2025.
• Across the five-year window, Receivables - Other soared 283.44% in 2022 and tumbled 96.91% in 2025, its largest moves.
• Year by year, Receivables - Other stood at $1.9 million in 2022, then climbed by 6.83% to $2.0 million in 2023, then sank by 90.09% to $200000.0 in 2024, then plunged by 77.0% to $46000.0 in 2025, then plunged by 93.48% to $3000.0 in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $3000.0 in Q1 2026, $46000.0 in Q4 2025, and $1.7 million in Q3 2025.